MARKET

MEIP

MEIP

MEI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.920
+0.030
+1.04%
After Hours: 2.920 0 0.00% 16:00 09/24 EDT
OPEN
2.890
PREV CLOSE
2.890
HIGH
2.950
LOW
2.860
VOLUME
193.24K
TURNOVER
--
52 WEEK HIGH
4.575
52 WEEK LOW
2.400
MARKET CAP
329.02M
P/E (TTM)
-4.8545
1D
5D
1M
3M
1Y
5Y
MEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
/PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present a company overview and business update at the 2021 Cantor Virtual Global Healthcare Con...
PR Newswire - PRF · 4d ago
Companies Like MEI Pharma (NASDAQ:MEIP) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St. · 09/07 13:03
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Sept. 3, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for an aggregate of 132,000 shares of the company's comm...
PR Newswire - PRF · 09/03 20:05
MEI Pharma, Inc. (MEIP) Reports Break-Even Earnings for Q4
Zacks.com · 09/02 21:45
MEI Pharma Widens Loss in Fiscal 2021 Amid Lower Revenue
MT Newswires · 09/02 16:55
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
Benzinga · 09/02 12:19
MEI Pharma to Present at Two Healthcare Conferences
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will present a company overview and business update at two upcoming investor conferences:
PR Newswire · 09/02 12:00
Earnings Scheduled For September 2, 2021
  Companies Reporting Before The Bell • Navios Maritime Holdings (NYSE:NM) is projected to report earnings for its second quarter.
Benzinga · 09/02 08:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MEIP. Analyze the recent business situations of MEI Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MEIP stock price target is 10.67 with a high estimate of 20.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 147
Institutional Holdings: 91.19M
% Owned: 80.93%
Shares Outstanding: 112.68M
TypeInstitutionsShares
Increased
38
5.05M
New
13
417.30K
Decreased
39
6.53M
Sold Out
9
687.78K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Christine White
Chief Executive Officer/President/Director
Daniel Gold
Chief Financial Officer/Secretary
Brian Drazba
Chief Operating Officer/General Counsel
David Urso
Senior Vice President/Director of Marketing
Brian Powl
Other
Richard Ghalie
Independent Director
Charles Baltic
Independent Director
Kevan Clemens
Independent Director
Cheryl Cohen
Independent Director
Frederick Driscoll
Independent Director
Nicholas Glover
Independent Director
Tamar Howson
Independent Director
Thomas Reynolds
No Data
About MEIP
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Webull offers kinds of MEI Pharma Inc stock information, including NASDAQ:MEIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEIP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MEIP stock methods without spending real money on the virtual paper trading platform.